Author: GENPREX, INC.

Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa® Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Cancer

June 22, 2026
Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy

April 21, 2026

Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa® Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Cancer